Bicuspid aortic valve (BAV) is one of the most common and heterogeneous congenital heart diseases, affecting approximately 0.5–2% of the population, often manifested by associated aortopathy. Of scientific interest is the search for new biomarkers reflecting the pathophysiological process in the vascular wall as a prediction of its dilatation in order to prevent a life-threatening condition.
The aim of the study was to clarify the predictive role of galectin-3 as a potential biomarker of the aneurysmal transformation of BAV-associated aortopathy.
47 patients were examined (22 patients with BAV, mean age 44 years; 25 volunteers, mean age 44 years). The measurement of the serum level of galectin-3 was carried out using an ELISA kit (Galectin 3 ELISA Kit). It has been established that an increased serum level of galectin-3 in patients with BAV-associated aortopathy may serve as a serological marker indicating a poor prognosis, accompanied by an increase in the size of the aorta diameter.

1. Argüeso, P., & Panjwani, N.. Focus on Molecules: Galectin-3. Experimental Eye Research, 2011, 92(1), 2–3.

2. Borger M. A. et al. The American Association for Thoracic Surgery consensus guidelines on bicuspid aortic valve–related aortopathy: Full online-only version // The Journal of thoracic and cardiovascular surgery. – 2018. – Т. 156. – № 2. – С. e41–e74.

3. Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis. Int J Cardiol. 2015;182:168–170.

4. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis treatment of acute, chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.

5. Fort-Gallifa I. et al. Galectin-3 in peripheral artery disease. Relationships with markers of oxidative stress and inflammation //In ternational journal of molecular sciences. – 2017. – Т. 18. – № 5. – С. 973.

6. Issa SF, Christensen AF, Lottenburger T, Junker K, Lindegaard H, Hørslev-Petersen K, Junker P. Within-day variation and influence of physical exercise on circulating Galectin-3 in patients with rheumatoid arthritis and healthy individuals. Scand J Immunol. 2015;82:70–75.

7. Johnston KW, Rutherford RB, Tilson MD, Shah DM, Hollier L, Stanley JC. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Sur­gery. J Vasc Surg. 1991;13:452-8.

8. Kimmenade RR, Kempers M, de Boer MJ, Loeys BL, Timmer­mans J. A clinical appraisal of different Z-score equations for aortic root assessment in the diagnostic evaluation of Marfan syndrome. Genet Med. 2013;15:528–532.

9. Kinoshita N, Mimura J, Obayashi C, Katsukawa F, Onishi S, Yamazaki H. Aortic root dilatation among young competitive athletes: echocardiographic screening of 1929 athletes between 15 and 34 years of age. Am Heart J. 2000;139:723–728.

10. Medvedeva EA, Berezin II, Surkova EA, Yaranov DM, Shchukin YV. Galectin-3 in patients with chronic heart failure: Association with oxidative stress, inflammation, renal dysfunction and prognosis. Minerva Cardioangiol. 2016;64:595–602.

11. Meeusen JW, Johnson JN, Gray A, Wendt P, Jefferies JL, Jaffe AS, Donato LJ, Saenger AK. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin Biochem. 2015;48:1337–1340.

12. Nagueh, S. F. Recommendations for the evaluation of leftvent­ricular diastolic function by echocardiography / S. F. Nagueh [et al.] // Journal of the American society of echocardiography. – 2009. – Vol. 22. – P. 108–133.

13. Newlaczyl AU, Yu LG. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett. 2011;313:123–128.

14. Nistri, S., Sorbo, M. D., Marin, M. Aortic root dilatation in young men with normally functioning bicuspid aortic valves. Heart, 1999, 82(1), 19–22.

15. Oliveira FL, Gatto M, Bassi N, Luisetto R, Ghirardello A, Punzi L, Doria A. Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood) 2015;240:1019–1028.

16. Papaspyridonos M., McNeill E., de Bono J. P., Smith A., Burnand K. G., Channon K. M., Greaves D. R. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler. Thromb. Vasc. Biol. 2008;28:433–440.

17. Mahadevia, R., Barker, A. J., Schnell, S., Entezari, P. Bicuspid aortic cusp fusion morphology alters aortic three-dimensional outflow patterns, wall shear stress, and expression of aortopathy. Circulation, 2014, 129(6), 673–682.

18. Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, Menini S. Galectin-3 in diabetic patients. Clin Chem Lab Med. 2014;52:1413–1423.

19. Saccon F, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A. Role of galectin-3 in autoimmune and non-autoimmune nephropathies. Autoimmun Rev. 2017;16:34–47.

20. Schindler EI, Szymanski JJ, Hock KG, Geltman EM, Scott MG. Short- and long-term biologic variability of galectin-3 and other cardiac biomarkers in patients with Stable heart failure and healthy adults. Clin Chem. 2016;62:360–366.

21. Stone J. R. et al. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases //Cardiovascular Pathology. – 2015. – Т. 24. – № 5. – С. 267–278.

22. Ward, C. Clinical significance of the bicuspid aortic valve. Heart, 2000, 83(1), 81–85.

23. Wolak A. et al. Aortic size assessment by noncontrast cardiac computed tomography: normal limits by age, gender, and body surface area // JACC: Cardiovascular Imaging. – 2008. – Т. 1. – № 2. – С. 200–209.